ENANTA PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect two Class III directors to serve until the 2028 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Lesley Russell

ENANTA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lesley Russell, MBChB, MRCP”): 14,574,902 for, 983,973 withheld, per its Form 8-K filed March 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following individuals as Class III directors of the Company:”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 4,459,467 for, 124,530 withheld.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: To elect two Class III directors to serve until the 2028 Annual Meeting of Stockholders or until their respective successors are elected and qualified: Mark G. Foletta

ENANTA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mark G. Foletta”): 14,935,940 for, 622,935 withheld, per its Form 8-K filed March 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders re-elected the following individuals as Class III directors of the Company:”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 4,507,084 for, 76,913 withheld.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR 2019 EQUITY INCENTIVE PLAN.

ENANTA PHARMACEUTICALS INC.’s own tally for this item (“2. To Approve an Amendment to Our 2019 Equity Incentive Plan”): 11,435,985 for, 4,085,303 against — passed, per its Form 8-K filed March 17, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved the amendment to our 2019 Equity Incentive Plan to increase the number of shares of Common Stock reserved for issuance under the plan by 800,000 shares.”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 3,697,270 for, 886,755 against.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation paid to our named executive officers, as disclosed in the proxy statement.

ENANTA PHARMACEUTICALS INC.’s own tally for this item (“4. To Approve, on an Advisory Basis, the Compensation Paid to the Company's Named Executive Officers”): 14,516,861 for, 1,039,888 against — passed, per its Form 8-K filed March 17, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved the advisory vote on executive compensation, referred to as a "say-on-pay" vote.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 47 managers: 4,179,915 for, 404,082 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 99 managers: 5,447,031 for, 372,769 against, 11,135 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation paid to our named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 46 managers: 4,331,320 1 year, 233,923 3 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 94 managers: 1,076,901 for, 30 against, 4,179,019 1 year, 34,615 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as Enanta's independent registered public accounting firm for the 2025 fiscal year.

ENANTA PHARMACEUTICALS INC.’s own tally for this item (“5. To Ratify the Appointment of PricewaterhouseCoopers LLP as Enanta's Independent Registered Public Accounting Firm for the 2025 Fiscal Year”): 17,740,127 for, 72,357 against — passed, per its Form 8-K filed March 17, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2025.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 4,583,856 for, 169 against.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.